Back to search
FDAFDA · Food and drugs·Recall number D-0657-2020

Panther Platinum 30000 Capsules, in green, black background with white, red text in hologram paper packaging, packaged in 2, 4, and 10 count blister cards, Motto International, Dallas, TX

Published January 22, 2020 · Recall initiated: December 17, 2019

Summary

FDA records drug Class I recall D-0657-2020, published January 22, 2020 and initiated December 17, 2019. Recalling firm: Motto International Corp; Status: Terminated; Reported quantity: 1 box; Lot: All lots remaining within expiry. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Marketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfil

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Motto International Corp
Distributor
TX
Lot
All lots remaining within expiry.
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Panther Platinum 30000 Capsules, in green, black background with white, red text in hologram paper packaging, packaged in 2, 4, and 10 count blister cards, Motto International, Dallas, TX recalled?

Yes. FDA published recall D-0657-2020 on January 22, 2020. Reported hazard: Marketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfil

What should I do if I have this product?

Voluntary: Firm initiated · Press Release